Correlation between morphology and EGFR mutations in lung adenocarcinomas. Significance of the micropapillary pattern and the hobnail cell type

Lung Cancer

Volumn 63, Issue 2, 2009, Pages 235-240

  Ninomiya, Hironori ^a   Hiramatsu, Miyako ^a   Inamura, Kentaro ^a   Nomura, Kimie ^a   Okui, Michiyo ^a   Miyoshi, Tatsu ^a   Okumura, Sakae ^b   Satoh, Yukitoshi ^a,b   Nakagawa, Ken ^b   Nishio, Makoto ^b   Horai, Takeshi ^b   Miyata, Satoshi ^c   Tsuchiya, Eiju ^d   Fukayama, Masashi ^e   Ishikawa, Yuichi ^a  

^a CANCER INSTITUTE   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Epidermal growth factor receptor (EGFR); Gefitinib; Hobnail cell type; Lung adenocarcinoma; Micropapillary pattern

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CELL STRUCTURE; CELL TYPE; CLASSIFICATION; CLINICAL FEATURE; EXON; FEMLE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 58049205542     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.04.017     Document Type: Article

References (26)

1. Amin M.B., Tamboli P., Merchant S.H., Ordonez N.G., Ro J., Ayala A.G., et al. Micropapillary component in lung adenocarcinoma. A distinctive histological feature with possible prognostic significance. Am J Surg Pathol 26 (2002) 358-364
2. Barbara A.H., David R., Marileila V.G., Dan G., Daniel C.C., Lynne B., et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 12 (2006) 7117-7125
3. Calvo E., and Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 24 (2006) 2158-2163
4. Cappuzzo F., Gregorc V., Rossi E., Cancellieri A., Magrini E., Paties C.T., et al. Gefitinib in pretreated non small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21 (2003) 2658-2663
5. Haneda H., Sasaki H., Lindeman N., Kawano O., Endo K., Suzuki E., et al. Correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol 36 (2006) 69-75
6. Hashimoto T., Tokuchi Y., Hayashi M., Kobayashi Y., Nishida K., Hayashi S., et al. Different subtypes of human lung adenocarcinoma caused by different etiological factors-evidence from p53 mutational spectra. Am J Pathol 157 (2000) 2133-2141
7. Hsieh R.K., Lim K.H., Kuo H.T., Tzen C.Y., and Huang M.J. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 128 (2005) 317-321
8. Japan Lung Cancer Society. General rules for clinical and pathological records of lung cancer. 5th ed. (1999), Kanehara and Co., Tokyo [in Japanese]
9. Kim Y.H., Ishii G., Goto K., Nagai K., Tsuta K., Shiono S., et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 10 (2004) 7311-7317
10. Kobayashi M., Takeuchi T., Bandobashi K., Uemura Y., Ogawa Y., Ohtsuki Y., et al. Diffuse micronodular pulmonary metastasis of lung adenocarcinoma predicts gefitinib response in association with epidermal growth factor receptor mutations. Anticancer Res 26 (2006) 1621-1626
11. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
12. Makimoto Y., Nabeshima K., Iwasaki H., Miyoshi T., Enatsu S., Shiraishi T., et al. Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours). Histopathology 46 (2005) 677-684
13. Matsumoto S., Iwakawa R., Kohno T., Suzuki K., Matsuno Y., Yamamoto S., et al. J. EGFR mutations in noninvasive bronchioloalveolar carcinoma. Int J Cancer 118 (2006) 2498-2504
14. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 1103-1109
15. Miyoshi T., Satoh Y., Okumura S., Nakagawa K., Shirakusa T., Tsuchiya E., et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis. Am J Surg Pathol 27 (2003) 101-109
16. Moasser M.M., Basso A., Averbuch S.D., and Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61 (2001) 7184-7188
17. Okubo K., Mark E.J., Flieder D., Wain J.C., Wright C.D., Moncure A.C., et al. Bronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survival. J Thorac Cardiovasc Surg 118 (1999) 702-709
18. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 (2000) 3159-3167
19. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. Egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
20. Powell C.A., Bueno R., Borczuk A.C., Caracta C.F., Richards W.G., Sugarbaker D.J., et al. Patterns of allelic loss differ in lung adenocarcinomas of smokers and nonsmokers. Lung Cancer 39 (2003) 23-29
21. Sanchez-Cespedes M., Ahrendt S.A., Piantadosi S., Rosell R., Monzo M., Wu L., et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 61 (2001) 1309-1313
22. Sasaki H., Endo K., Takada M., Kawahara M., Kitahara N., Tanaka H., et al. EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 3 (2007) 324-328 58
23. Toyooka S., Matsuo K., Shigematsu H., Kosaka T., Tokumo M., Yatabe Y., et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 19 (2007) 5763-5768
24. Travis W.D., Brambilla E., Muller-Hermelink H., and Harris C. WHO classification of tumors. Pathology & genetics tumors of the lung, pleura, thymus and heart (2004), IARC Press, Lyon
25. Inamura K., Togashi Y., Nomura K., Ninomiya H., Hiramatsu M., Okui M., et al. Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas. Lung Cancer 57 (2007) 201-206
26. Yatabe Y., Kosaka T., Takahashi T., and Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29 (2005) 633-639